Published: Nov, 2016
AbbVie, Inc. and Allergan have been the leaders in the global exocrine pancreatic insufficiency market in 2014 with a massive share of 95.4%. AbbVie’s key product in the market, Creon, is extensively sold within the U.S., the only region where it is marketed.
According to a research report released by Transparency Market Research, the global exocrine pancreatic insufficiency market is highly consolidated. In 2014, a mere four players took up the entirety of the market value. This may change over time as the prevalence of EPI increases and newer players may be allowed entry by relaxing of regulatory norms.
The global exocrine pancreatic insufficiency market is expected to expand at a CAGR of 8.3% within a forecast period from 2015 to 2023, in terms of revenue. This revenue is expected to reach US$1.63 bn by the end of 2016 and US$2.85 bn by the end of 2023.
U.S. Leads in Development of EPI Treatment
By far, North America has led the global exocrine pancreatic insufficiency market in terms of revenue, demand, and growth rate. By the end of 2023, the exocrine pancreatic insufficiency market in the U.S. is expected to reach US$1.27 bn. The key driver for this region’s market is the massive rate of research and development for EPI treatment, which itself is a consequence of a large and growing number of patients suffering from diseases such as chronic pancreatitis and cystic fibrosis. As many as 40% of the U.S. population has been affected by cystic fibrosis, according to a study posted by Aptalis (Allergan).
Cystic Fibrosis and Diabetes on the Rise Globally
“The top reason for the proliferation of the global exocrine pancreatic insufficiency market at the moment is the massive number of people suffering from diabetes. The number of diabetics around the world is expected to reach an astronomical number of 366 mn by 2030, according to the American Diabetes Association,” states a TMR analyst. Diabetes is the top factor known to significantly increase the chances of a patient contracting chronic pancreatitis and cystic fibrosis, the two leading factors that give rise to EPI.
Aptalis further stated in 2013 that almost 90% of the patients suffering from cystic fibrosis end up with exocrine pancreatic insufficiency. A similarly high number of people suffering from chronic pancreatitis also suffer from EPI. In the U.S., as much as 5% of the adult population might be suffering from chronic pancreatitis, of which at most 40% will develop EPI over time. This is a highly concerning ration for the global exocrine pancreatic insufficiency market, which is planning a higher rate of research and development to cope with the increasing demand for effective treatment.
Regulatory Pressure a Negative Factor for EPI Treatment Providers
On one hand, the sales of pancrelipase products can be performed easily as they are considered to be over-the-counter drugs in many regions including the U.S. and several countries in Europe. However, the global exocrine pancreatic insufficiency market is still affected by the giant and complex regulatory framework around the market in terms of approval of drug quality and sales approvals, as set by the FDA. This is stifling the global exocrine pancreatic insufficiency market by denying entry for a lot of players.
“Meanwhile, many players in the global exocrine pancreatic insufficiency market are currently looking at emerging economies for growth opportunities. Countries especially from Asia Pacific are showing a great scope of acceptance for EPI treatments and solutions, owing to a quick development rate of healthcare infrastructure, added spending on healthcare services, and a growing EPI patient pool,” adds the analyst.
The information presented in this review is based on a Transparency Market Research report, titled, “Exocrine Pancreatic Insufficiency Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2015 - 2023.”
Key Segments of the Global Exocrine Pancreatic Insufficiency Market
Global Exocrine Pancreatic Insufficiency Market, by Therapeutics
- Pancreatic Enzyme Replacement Therapy (PERT) Drugs
- Exocrine Pancreatic Insufficiency Drugs, Pipeline Analysis, Sollpura (Liprotamase)
Global Exocrine Pancreatic Insufficiency Market, by Diagnostic Tests
- Blood Tests
- Endoscopic Ultra-Sonography (EUS)
- Magnetic Resonance Imaging (MRI)
- CT Scanning
Global Exocrine Pancreatic Insufficiency Market, by Geography
- North America
- Rest of North America
- Rest of Europe
- Asia Pacific
- Rest of APAC
- Latin America
- Rest of LATAM
- Rest of the World
- South Africa
- Rest of RoW
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453